ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma

Cancer Research

Volumn 63, Issue 1, 2003, Pages 140-148

  Hernan, Roberto ^b   Fasheh, Rami ^b   Calabrese, Christopher ^b   Frank, Adrian J ^b   Maclean, Kirsteen H ^b   Allard, David ^a   Barraclough, Roger ^a   Gilbertson, Richard J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; ERLOTINIB; LY 249002; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BASEMENT MEMBRANE; BREAST CARCINOMA; CANCER GENETICS; CANCER INVASION; CANCER MORTALITY; CELL MIGRATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; MOLECULAR MECHANICS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; S100A4 GENE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BRAIN STEM NEOPLASMS; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, REPORTER; HUMANS; LUCIFERASES; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIDS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; S100 PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037224320     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., and Hynes, N. E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.
2. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H., and Hung, M. C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol., 3: 245-252, 2001.
3. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation, Nat. Cell Biol., 3: 973-982, 2001.
4. Hudziak, R. M., Lewis, G. D., Shalaby, M. R., Eessalu, T. E., Aggarwal, B. B., Ullrich, A., and Shepard, H. M. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 85: 5102-5106, 1988.
5. Naume, B., Borgen, E., Kvalheim, G., Karesen, R., Qvist, H., Sauer, T., Kumar, T., and Nesland, J. M. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin. Cancer Res., 7: 4122-4129, 2001.
6. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
7. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
8. Yarden, Y., and Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2: 127-137, 2001.
9. Gilbertson, R. J., Clifford, S. C., MacMeekin, W., Meekin, W., Wright, C., Perry, R. H., Kelly, P., Pearson, A. D., and Lunec, J. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res., 58: 3932-3941, 1998.
10. Yu, D., Wang, S. S., Dulski, K. M., Tsai, C. M., Nicolson, G. L., and Hung, M. C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res., 54: 3260-3266, 1994.
11. Yu, D. H., and Hung, M. C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene, 6: 1991-1996, 1991.
12. Gambaletta, D., Marchetti, A., Benedetti, L., Mercurio, A. M., Sacchi, A., and Falcioni, R. Cooperative signaling between α(6)β(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J. Biol. Chem., 275: 10604-10610, 2000.
13. Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J., and Kumar, R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem., 273: 28238-28246, 1998.
14. Spencer, K. S., Graus-Porta, D., Leng, J., Hynes, N. E., and Klemke, R. L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol., 148: 385-397, 2000.
15. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.
16. Gilbertson, R. J., Perry, R. H., Kelly, P. J., Pearson, A. D., and Lunec, J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res., 57: 3272-3280, 1997.
17. Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., and Meyers, P. A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol., 17: 2781-2788, 1999.
18. Herms, J. W., Behnke, J., Bergmann, M., Christen, H. J., Kolb, R., Wilkening, M., Markakis, E., Hanefeld, F., and Kretzschmar, H. A. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J. Pediatr. Hematol. Oncol., 19: 510-515, 1997.
19. Mazzucchelli, L. Protein S100A4: too long overlooked by pathologists? Am. J. Pathol., 160: 7-13, 2002.
20. 2+-binding protein family. Genes Dev., 3: 1086-1093, 1989.
21. Levett, D., Flecknell, P. A., Rudland, P. S., Barraclough, R., Neal, D. E., Mellon, J. K., and Davies, B. R. Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am. J. Pathol., 160: 693-700, 2002.
22. Davies, B. R., O'Donnell, M., Durkan, G. C., Rudland, P. S., Barraclough, R., Neal, D. E., and Mellon, J. K. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J. Pathol., 196: 292-299, 2002.
23. Rudland, P. S., Platt-Higgins, A., Renshaw, C., West, C. R., Winstanley, J. H., Robertson, L., and Barraclough, R. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res., 60: 1595-1603, 2000.
24. Davies, M. P., Rudland, P. S., Robertson, L., Parry, E. W., Jolicoeur, P., and Barraclough, R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene, 13: 1631-1637, 1996.
25. Ambartsumian, N. S., Grigorian, M. S., Larsen, I. F., Karlstrom, O., Sidenius, N., Rygaard, J., Georgiev, G. and Lukanidin, E. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene, 13: 1621-1630, 1996.
26. Gilbertson, R. J., Pearson, A. D., Perry, R. H., Jaros, E., and Kelly, P. J. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer, 71: 473-477, 1995.
27. Gilbertson, R., Wickramasinghe, C., Hernan, R., Balaji, V., Hunt, D., Jones-Wallace, D., Crolla, J., Perry, R., Lunec, J., Pearson, A., and Ellison, D. Clinical and molecular stratification of disease risk in medulloblastoma. Br. J. Cancer, 85: 705-712, 2001.
28. Packer, R. J. Childhood medulloblastoma: progress and future challenges. Brain Dev., 21: 75-81, 1999.
29. Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E. L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol., 14: 1675-1680, 1996.
30. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.
31. Di Marco, E., Pierce, J. H., Knicley, C. L., and Di Fiore, P. P. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol. Cell. Biol., 10: 3247-3252, 1990.
32. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J., 19: 3159-3167, 2000.
33. MacDonald, T. J., Brown, K. M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Y., Packer, R. J., Cogen, P., and Stephan. D. A. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet., 29: 143-152, 2001.
34. Desai, K. V., Xiao, N., Wang, W., Gangi, L., Greene, J., Powell, J. L., Dickson, R., Furth, P., Hunter, K., Kucherlapati, R., Simon, R., Liu, E. T., and Green, J. E. Initiating oncogenic event determines gene expression patterns of human breast cancer models. Proc. Natl. Acad. Sci. USA, 99: 6967-6972, 2002.
35. Kumar, R., and Yarmand-Bagheri, R. The role of HER2 in angiogenesis. Semin. Oncol., 28: 27-32. 2001.
36. Bosc, D. G., Goueli, B. S., and Janknecht, R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene, 20: 6215-6224, 2001.
37. Fruhwald, M. C., O'Dorisio, M. S., Dai, Z., Tanner, S. M., Balster, D. A., Gao, X., Wright, F. A., and Plass, C. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas: implications for tumor biology and potential clinical utility. Oncogene, 20: 5033-5042, 2001.
38. Sasaki, H., Auclair, D., Fukai, I., Kiriyama, M., Yamakawa, Y., Fujii, Y., and Chen, L. B. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in non-small cell lung carcinomas. Cancer (Phila.), 92: 843-848, 2001.
39. Yoshida, K., Yoshitomo-Nakagawa, K., Seki, N., Sasaki, M., and Sugano, S. Cloning, expression analysis, and chromosomal localization of BH-protocadherin (PCDH7), a novel member of the cadherin superfamily. Genomics, 49: 458-461, 1998.
40. Tanno, B., Negroni, A., Vitali, R., Pirozzoli, M. C., Cesi, V., Mancini, C., Calabretta, B., and Raschelia, G. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J. Biol. Chem., 277: 23172-23180, 2002.
41. Zimmermann, S., and Moelling, K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science (Wash. DC), 286: 1741-1744, 1999.
42. Mograbi, B., Bocciardi, R., Bourget, I., Busca, R., Rochet, N., Farahi-Far, D., Juhel, T., and Rossi, B. Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells. J. Biol. Chem., 276: 45307-45319, 2001.
43. Slicbenmyer, W. J., and Fry, D. W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin. Oncol., 28: 67-79, 2001.
44. Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res., 61: 7184-7188, 2001.
45. Zeltzer, P. M., Boyett, J. M., Finlay, J. L., Albright, A. L., Rorke, L. B., Milstein, J. M., Allen. J. C., Stevens, K. R., Stanley, P., Li, H., Wisoff, J. H., Geyer, J. R., McGuire-Cullen, P., Stehbens, J. A., Shurin, S. B., and Packer, R. J. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J. Clin. Oncol., 17: 832-845, 1999.
46. Wilson, J., and Balkwill, F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol., 12: 113-120, 2002.
47. Brigati, C., Noonan, D. M., Albini, A., and Benelli, R. Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis, 19: 247-258, 2002.
48. Balkwill, F., and Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 357: 539-545, 2001.
49. Rossi, M. L., Buller, J. R., Heath, S. A., Carey, M. P., Carboni, P., Jr., Koutsoubelis, G., and Coakham, H. B. The monocyte/macrophage infiltrate in 35 medulloblastomas: a paraffin-wax study, Tumori, 77: 36-40, 1991.
50. Azenshtein, E., Luboshits, G., Shina, S., Neumark, E., Shahbazian, D., Well, M., Wiglet, N., Keydar, I., and Ben-Baruch, A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res., 62: 1093-1102, 2002.
51. Negus, R. P., Stamp, G. W., Hadley, J., and Balkwill, F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol., 150: 1723-1734, 1997.
52. Janssen, A. M., van Duijn, W., Kubben, F. J., Griffioen, G., Lamers, C. B., van Krieken, J. H., van de Velde, C. J., and Verspaget, H. W. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin. Cancer Res., 8: 1889-1896, 2002.
53. Jasani, B., and Schmid, K. W. Significance of metallothionein overexpression in human tumours. Histopathology, 31: 211-214, 1997.
54. Lazo, J. S., Kuo, S. M., Woo, E. S., and Pitt, B. R. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem. Biol. Interact., 111-112: 255-262, 1998.
55. Takeshita, S., Kikuno, R., Tezuka, K., and Amann, E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem. J., 294: 271-278, 1993.
56. Cohn, M. A., Hjelmso, I., Wu, L. C., Guldberg, P., Lukanidin, E. M., and Tulchinsky, E. M. Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer. Nucleic Acids Res., 29: 3335-3346, 2001.
57. Chen, D., Davies, M. P., Rudland, P. S., and Barraclough, R. Transcriptional down-regulation of the metastasis-inducing S100A4 (p9Ka) in benign but not in malignant rat mammary epithelial cells by GC-factor. J. Biol. Chem., 272: 20283-20290, 1997.